Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Kaufen priligy im Online-Shop. Wirkung ist gut, kommt sehr schnell, innerhalb von 5-7 Minuten. levitra was nur nicht versucht, verbrachte eine Menge Geld und Nerven, und geholfen hat mir nur dieses Tool.


Review Article
Dietary supplements for body-weight reduction: a systematicreview1,2 ABSTRACT
tions such as type 2 diabetes, heart disease, cancer, and osteoar- Background: Compliance with conventional weight-management
thritis of weight-bearing joints increases with body weight (2–5), programs is notoriously poor, and a plethora of over-the-counter and these conditions lead to substantial economic costs in the slimming aids are sold with claims of effectiveness.
total health care budget (6). One factor responsible for over- Objective: The objective of the study was to assess the evidence
weight and obesity is a continuous decrease in energy expendi- from rigorous clinical trials, systematic reviews, and meta-analyses ture from physical activity during recent decades (7, 8). Com- on the effectiveness of dietary supplements in reducing body weight.
pliance with conventional weight-management programs is Design: The study was a systematic review. Literature searches were
notoriously poor, which indicates a need for safe, effective, and conducted on Medline, Embase, Amed, Cinahl, and the Cochrane acceptable therapeutic options. It is therefore not surprising to Library until March 2003. Hand searches of medical journals, the see the marketing of a plethora of over-the-counter slimming aids authors’ own files, and bibliographies of identified articles were with claims of effectiveness (9, 10). The aim of this systematic conducted. There were no restrictions regarding the language of review is to critically assess the evidence from rigorous clinical publication. The screening of studies, selection, validation, data trials, systematic reviews, and meta-analyses on the effective- extraction, and the assessment of methodologic quality were per- ness of dietary supplements in reducing body weight.
formed independently by the 2 reviewers. To be included, trials wererequired to be randomized and double-blind. Systematic reviews andmeta-analyses of dietary supplements were included if they were based on the results of randomized, double-blind trials.
Results: Five systematic reviews and meta-analyses and 25 addi-
Systematic literature searches were conducted to identify all tional trials were included and reviewed. Data on the following randomized clinical trials (RCTs), systematic reviews, and meta- dietary supplements were identified: chitosan, chromium picolinate, analyses of dietary supplements for body weight reduction. Data Ephedra sinica, Garcinia cambogia, glucomannan, guar gum, sources were Medline, Embase, Amed, Cinahl, and the Cochrane hydroxy-methylbutyrate, plantago psyllium, pyruvate, yerba maté, Library. The search terms used were dietary supplements, food and yohimbe. The reviewed studies provide some encouraging data supplements, herbal products, phytotherapy, overweight, obe- but no evidence beyond a reasonable doubt that any specific dietary sity, weight loss, slimming, and derivatives of these. Each data- supplement is effective for reducing body weight. The only excep- base was searched from its inception until March 2003. Hand tions are E. sinica– and ephedrine-containing supplements, which searches of relevant medical journals and of the authors’ own have been associated with an increased risk of adverse events.
files were conducted. The bibliographies of all articles located Conclusions: The evidence for most dietary supplements as aids in
were searched for further studies. There were no restrictions reducing body weight is not convincing. None of the reviewed di- regarding the language of publication (11).
etary supplements can be recommended for over-the-counter To be included, trials were required to state that they were Am J Clin Nutr 2004;79:529 –36.
randomized and double-blind. Systematic reviews and meta-analyses of dietary supplements were included if based on the KEY WORDS
Overweight, obesity, weight reduction, com- results of randomized, double-blind trials. Studies assessing plementary medicine, alternative medicine, herbal medicine, dietary acute effects only were excluded. All studies were selected ac- supplements, chitosan, guar, chromium, ephedra, psyllium, garcinia cording to defined criteria, and data were validated and extractedin a systematic manner. Methodologic quality was evaluated byusing the system developed by Jadad et al (12). The screening and INTRODUCTION
selection of studies, data extraction, validation, and the assessment The number of persons whose body weight is greater than their of methodologic quality were performed independently by the 2 ideal is increasing, particularly in developed countries. In theUnited States, for instance, more than half of the adult population 1 From Complementary Medicine, Peninsula Medical School, Universi- must now be classified as overweight or obese. On the basis of a ties of Exeter and Plymouth, Exeter, United Kingdom.
normal body mass index (BMI; in kg/m2) ranging from 18.5 to Address reprint requests and correspondence to MH Pittler, Complemen- tary Medicine, Peninsula Medical School, Universities of Exeter and Ply- 24.9, 31% of the US adult population is obese (BMI ͧ 30), and mouth, 25 Victoria Park Road, Exeter EX2 4NT, United Kingdom. E-mail: an additional 34% is overweight (BMI ͧ 25; 1). Excess body weight is one of the most important risk factors for all-cause morbidity and mortality. The likelihood of developing condi- Accepted for publication September 24, 2003.
Am J Clin Nutr 2004;79:529 –36. Printed in USA. 2004 American Society for Clinical Nutrition reviewers. Disagreements in the evaluation of studies were largely All 3 trials that reported on adverse events and an additional trial due to reading errors and were resolved through discussion.
using niacin-bound chromium (Table 1) reported no adverseevents in patients receiving chromium.
Ephedra sinica
Five systematic reviews and meta-analyses based on the re- E. sinica, or ma-huang, is an evergreen shrub native to central sults of double-blind RCTs and 25 additional double-blind RCTs Asia (50). Ephedrine, the primary active constituent of the bo- met all inclusion criteria. The identified evidence relates to tanical E. sinica, has been studied alone and in combination with ayurvedic herbal preparations, chitosan, chromium picolinate, caffeine. A systematic review of 5 double-blind trials, including Ephedra sinica, Garcinia cambogia, glucomannan, guar gum, 2 trials whose format as randomized or nonrandomized is not hydroxy-methylbutyrate, plantago psyllium, pyruvate, yerba clear, concluded that the combination of ephedrine and caffeine maté, and yohimbe (Tables 1 and 2).
is effective for reducing body weight and appears to outweigh therisks (Table 2) (38). The most rigorous review to date (39) as- Ayurvedic preparations
sessed human studies with ͧ 8 wk of follow-up and concluded We identified one double-blind RCT assessing ayurvedic that E. sinica and ephedrine promote a modest short-term weight herbal preparations (13). Included patients whose body weight loss of Ȃ0.9 kg/mo more than does placebo (Table 2). The in- was ͧ 20% greater than their ideal according to the Life Insur- take of those supplements, however, is associated with a 2.2- to ance Corporation of India received daily either indistinguishable 3.6-fold increase in odds of psychiatric, autonomic, or gastroin- placebo or ayurvedic preparations (Table 1) plus 750 mg testinal symptoms and heart palpitations. Because of safety Triphala/d. Patients in the treatment group experienced a reduc- concerns, the FDA is now taking several regulatory actions tion in body weight ranging between 7.9 and 8.2 kg, which with regard to ephedra and ephedrine-containing supplements differed significantly from the reduction seen with placebo.
Garcinia cambogia
Chitosan is a cationic polysaccharide, which is produced from Hydroxycitric acid is obtained from extracts of G. cambogia chitin, a substance derived from the exoskeleton of crustaceans.
and has been shown to inhibit citrate cleavage enzyme, suppress It is promoted as a remedy to reduce fat absorption (41), and data de novo fatty acid synthesis and food intake, and decrease body from preclinical studies exist to support this notion (42– 44).
weight gain (20). We identified a double-blind RCT, which However, data from our meta-analysis of 5 double-blind RCTs, tested the effects of 3 g G. cambogia extract/d, which contained which included patients who were described as either obese, 50% hydroxycitric acid, in patients with an average BMI of 32 overweight, or having 10 –25% excess body weight, indicated (20). The results suggest the absence of a significantly greater serious methodologic limitations of the clinical evidence (36).
weight loss in the treatment group than in the placebo group. Two The meta-analysis concluded that the effectiveness of chitosan further double-blind RCTs report effects in favor of treatment for body-weight reduction is not established beyond a reasonable with G. cambogia compared with placebo (Ramos et al, unpub- doubt. We identified 5 further double-blind RCTs (Table 1) as- lished observations; cited in 20, 21). This is supported by a trial sessing overweight or obese patients that had been published testing the effects of hydroxycitric acid (22). Other double-blind since the meta-analysis. Overall, the evidence available in the RCTs, however, that tested G. cambogia extract– or hydroxy- literature indicates that there is considerable doubt that chitosan citric acid– containing combination preparations with or without is effective for reducing body weight in humans. Adverse events dietary alterations (Kaats et al, unpublished observations; cited most frequently included gastrointestinal symptoms such as con- in 20, 23–25) report conflicting results. Overall, the evidence for stipation and flatulence (Tables 1 and 2).
G. cambogia is not compelling. Adverse events are reported inthe reviewed trials and are listed in Table 1.
Chromium picolinate
Chromium, an essential trace mineral and cofactor to insulin, enhances insulin activity and has been the subject of studies Glucomannan is a component of konjac root, derived from assessing its effects in carbohydrate, protein, and lipid metabo- Amorphophallus konjac C. Koch. Its chemical structure is sim- lism (45– 47). Reported effects include an increase in lean body ilar to that of galactomannan from guar gum (see below) and mass, a decrease in percentage body fat, and an increase in the comprises a polysaccharide chain of glucose and mannose (53).
basal metabolic rate (19, 45, 48). Chromium picolinate is an We identified one double-blind RCT including patients with organic compound of trivalent chromium and picolinic acid, a body weight ͧ20% over their ideal (26). The report suggests naturally occurring derivative of tryptophan. Our meta-analysis significantly greater weight loss in the treatment group than in the included 10 double-blind RCTs (Table 2). The results suggest a placebo group. There were no adverse events in the treatment relatively small reduction of 1.1–1.2 kg (ie, 0.08 – 0.2 kg/wk) group. Independent replication of this trial is warranted.
compared with placebo during an intervention period of 6 –14 wkin patients with an average BMI of 28 –33 (37). By comparison, a diet with a provision of 3300 kJ/d achieves a mean weight loss Whether guar gum, a dietary fiber derived from the Indian of Ȃ1.5–2.5 kg/wk, and a more moderate energy restriction to cluster bean (Cyamopsis tetragonolobus), is effective in lower- 5000 kJ/d results in a weight loss of 0.5– 0.6 kg/wk (49). There- ing body weight was assessed in our meta-analysis (40). Twenty fore, it seems that the observed effect with chromium picolinate double-blind, placebo-controlled RCTs were included, and the is, although statistically significant, not clinically meaningful.
data from 11 trials were statistically pooled. The results of the DIETARY SUPPLEMENTS FOR BODY-WEIGHT REDUCTION TABLE 1
Randomized, double-blind trials of dietary supplements for body-weight reduction1
flatulence, stoolbulkiness,bloating, nausea,heartburn consume a 5000-kJ/ddiet; exercise wasencouraged TABLE 1 (Continued)
mass decreaseand P ҃ 0.06for lean massincrease 1 NR, not reported; NA, not applicable.
2 Quantification of the likelihood that bias is inherent in a trial, based on the description of randomization, blinding, and withdrawals (12).
3 n randomly assigned/n analyzed.
4 Unpublished observations, cited in reference 20.
meta-analysis suggest that guar gum is not effective in reducing spect to fat mass (27, 28), while at least a trend toward an increase body weight. The agreement between the individual RCTs con- in lean body mass was reported from all trials, including those in firms the overall result of the meta-analysis. Adverse events which it is unclear whether the patients and care providers were reported in the reviewed trials predominately relate to the gas- blinded. Thus, there are encouraging data that require further independent replication. Only 2 of the 4 trials provided data onadverse events (54), and they reported no such events in patients Hydroxy-methylbutyrate
treated with ␤-hydroxy-␤-methylbutyrate.
␤-Hydroxy-␤-methylbutyrate is a metabolite of leucine that has shown anticatabolic actions through inhibiting protein break- Plantago psyllium
down (54). ␤-Hydroxy-␤-methylbutyrate is available as a dietarysupplement and is primarily used by bodybuilders as a supportive Psyllium is a water-soluble fiber derived from the husks of ripe measure to induce changes in body composition. The searches seeds from Plantago ovata (50). We identified one double-blind yielded 4 RCTs reported in 3 articles (54, 27, 28). Two double- RCT, which included patients with type 2 diabetes and a mean blind RCTs reported significant intergroup differences with re- BMI of 29 (29). There were no significant changes in body DIETARY SUPPLEMENTS FOR BODY-WEIGHT REDUCTION TABLE 2
Systematic reviews and meta-analyses of dietary supplements for body-weight reduction1
to change theireating habitsand to exerciseregularly hypertension (7),upper gastrointestinalsymptoms (88),headache (16), 1 RCTs, randomized controlled trials; NR, not reported; NA, not applicable.
2 n randomly assigned/n analyzed.
3 Not defined in original trials.
4 Data from double-blind, placebo-controlled trials are presented; it is unclear whether 2 of the 5 studies were randomized.
5 Data from all identified studies are presented.
6 Data from controlled trials are presented.
weight in either the treatment or placebo group. The authors results of that study indicated that this combination preparation report excellent tolerance of psyllium.
might potentially be effective in lowering body weight. Adverseevents were not reported.
Pyruvate is generated in the body via glycolysis, and supple- mentation with pyruvate seems to enhance exercise performance Yohimbe (Pausinystalia yohimbe) is a tall evergreen tree that and improve measures of body composition (55, 56). Two is native to Central Africa. Yohimbine, an ␣-2 receptor antago- double-blind RCTs, which included patients with BMIs of ͧ25, nist, is the main active constituent of the ground bark of P. assessed the effects of pyruvate supplementation (30, 31). None yohimbe. Most clinical studies relate to the effects of this isolated of these studies reported significantly greater effects on weight constituent of yohimbe bark. We identified 3 double-blind RCTs, reduction than were seen with placebo. One (30) reported a which included patients who were Œ 15–20% over their ideal significant body-weight reduction of 1.2 kg from baseline, while body weight or had a BMI ranging between 28 and 48 (33–35).
both reported significant reductions in fat mass and percentage These trials report conflicting results (Table 1). At present, there- body fat from baseline. Considering the evidence available from fore, it is unclear whether yohimbine is effective in reducing rigorous clinical trials, the case of pyruvate as an aid to body- body weight. Few adverse events were reported.
composition changes and weight loss is weak. No adverse eventsare reported in one trial, and the other did not report on adverseevents (Table 1).
The data from published double-blind RCTs, systematic re- Yerba maté
views, and meta-analyses are encouraging in some cases, but Yerba maté (Ilex paraguariensis) is an evergreen tree that is they provide little convincing evidence that any specific dietary native to South America. In a combination preparation also con- supplement is effective in reducing body weight. The only ex- taining guarana (Paullinia cupana) and damiana (Turnera dif- ceptions are E. sinica– and ephedrine-containing dietary supple- fusa), it was tested in patients with a BMI of 26 –30 (32). I. ments. These remedies, however, have been associated with an paraguariensis and in particular P. cupana contain relatively increased risk of adverse events. The relative paucity of compel- large amounts of caffeine and have been shown by ultrasound ling evidence to suggest the effectiveness of dietary supplements scanning to prolong gastric emptying time (32). The descriptive in weight loss confirms the findings of earlier reviews (57).
Lifestyle changes including dieting and regular physical ex- of the evidence involved a degree of judgment in some cases, ercise are the basis for successful long-term weight loss, and which is another potential source of bias. However, we used a limited evidence exists to support the effectiveness of pharma- standard scale (12) to assess important criteria of methodologic cotherapeutic options other than orlistat and sibutramine (58, quality. This scale was also used in 4 of the 5 systematic reviews 59). Notoriously poor compliance with conventional weight- and meta-analyses. The methodologic quality of the evidence management programs and the popularity of complementary and was combined in an informal process with the type of evidence alternative medicine have created a ready market for nonpre- (eg, RCT or meta-analysis) and the volume of evidence to pro- scription weight-loss products. Data from a US survey of a ran- duce an indication of weight. This process of appraising the dom population sample of almost 15 000 adults, for instance, clinical evidence was performed independedntly by the 2 review- showed the common use of nonprescription weight-loss prod- ucts, particularly among young obese women. It is interesting In conclusion, according to our findings, the evidence for most that 8% of women with no excess body weight were also reported dietary supplements as aids in reducing body weight is not con- vincing. None of the reviewed dietary supplements can be rec- Although these preparations are popular, given the lack of convincing data on effectiveness (60), even minor adverse events MP was responsible for the conception and design of the study. MP and EE shift the delicate risk-benefit balance against their use. There is were responsible for the drafting of the manuscript, critical revision of the no convincing evidence, for instance, that guar gum is more manuscript for important intellectual content, and for final approval of the effective than placebo (Table 2), whereas adverse events such as manuscript. Neither of the authors had any conflicts of interest.
diarrhea, nausea, and flatulence were severe enough for 3% of thepatients in trials included in our meta-analysis to withdraw.
These findings are corroborated by other reports in the literature REFERENCES
(61– 63). In addition, it has been suggested that guar gum may 1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends cause possible drug interactions such as a potentiation of the in obesity among US adults 1999 –2000. JAMA 2002;288:1723–7.
effects of insulin and a decreased absorption of oral contracep- 2. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of tives (64). There are similar findings with respect to chromium 3. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk picolinate (Table 2), whose data suggest risks caused by chro- of developing common chronic diseases during a 10-year period. Arch mosome damage (65). This possibility was not confirmed later in animal experiments (66) or in studies involving humans (67).
4. National Task Force on the Prevention and Treatment of Obesity. Over- More recently, however, it was suggested that chromium pico- weight, obesity and health risk. Arch Intern Med 2000;160:898 –904.
linate enhances the rate of appearance of lethal mutations and 5. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305–13.
female sterility in Drosophila melanogaster (68). Two clinical 6. World Health Organization. Obesity: preventing and managing the cases of young men who developed acute rhabdomyolysis were global epidemic. Geneva: World Health Organization, 1998.
linked with chromium picolinate taken as part of an exercise 7. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? Br Med J regimen (69, 70). Severe renal impairment was reported in a 8. Heini AF, Weinsier RL. Divergent trends in obesity and fat intake pat- 33-y-old woman who took chromium picolinate (71). Another terns: the American paradox. Am J Med 1997;102:259 – 64.
case involved a 32-y-old man who ingested 1 mg chromium 9. Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss picolinate/d for 4 d and subsequently presented with acute gen- products. Results of a multistate survey. JAMA 2001;286:930 –5.
eralized exanthematous pustulosis (72). Case reports are rarely 10. Miles J, Petrie C, Steel M. Slimming on the internet. J R Soc Med conclusive evidence for establishing causality. These examples, 11. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact however, indicate that risks may be involved when taking dietary of language bias in meta-analyses of controlled trials: empirical study.
We aimed to identify all double-blind RCTs and all systematic 12. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of reviews and meta-analyses based on double-blind RCTs. The randomised clinical trials: is blinding necessary? Control Clin Trials potential incompleteness of the citation tracking is one of the 13. Paranjpe P, Patki P, Patwardhan B. Ayurvedic treatment of obesity: a limitations of this systematic review and, indeed, of systematic randomised double-blind, placebo-controlled clinical trial. J Ethnophar- reviews in general. Although strong efforts were made to retrieve all relevant data, it is conceivable that some studies were not 14. Wuolijoki E, Hirvela¨ T, Ylitalo P. Decrease in serum LDL cholesterol found. The distorting effects on systematic reviews arising from with microcrystalline chitosan. Methods Find Exp Clin Pharmacol 1999; publication bias and location bias are well documented (73–75).
15. Schiller RN, Barrager E, Schauss AG, Nichols EJ. A randomized, In complementary medicine journals, positive findings may be double-blind, placebo-controlled study examining the effects of a rap- overrepresented (76, 77), and positive conclusions may be fa- idly soluble chitosan dietary supplement on weight loss and body com- vored at the expense of methodologic quality (78). There is also position in overweight and mildly obese individuals. J Am Nutraceut evidence for the tendency of positive findings to be published in 16. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomised, double blind English-language journals, (79) and for some European journals trial of chitosan for body weight reduction. Eur J Clin Nutr 1999;53: not to be indexed in major medical databases (80). It is therefore problematic to restrict literature searches to the language of pub- 17. Ho SC, Tai ES, Eng PHK, Tan CE, Fok ACK. In the absence of dietary lications and databases used. For this study we searched data- surveillance chitosan does not reduce plasma lipids or obesity in hyper- bases with a focus on the American and European literature and cholesterolaemic obese Asian subjects. Singapore Med J 2001;42:6 –10.
18. Girola M, De Bernardi M, Contos S, et al. Dose effect in lipid-lowering those that specialize in complementary medicine. There were no activity of a new dietary integrator (Chitosan, Garcinia cambogia ex- restrictions in terms of publication language. We are therefore tract and chrome). Acta Toxicol Ther 1996;17:25– 40.
confident that the search strategy minimized bias. The appraisal 19. Crawford V, Scheckenbach R, Preuss HG. Effects of niacin-bound chro- DIETARY SUPPLEMENTS FOR BODY-WEIGHT REDUCTION mium supplementation on body composition in overweight African- 46. Offenbacher EG, Pi-Sunyer FX. Chromium in human nutrition. Annu American women. Diabet Obes Metab 1999;1:331–7.
20. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, 47. Mertz W. Chromium in human nutrition: a review. J Nutr 1993;123: Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential anti- obesity agent. JAMA 1998;280:1596 – 600.
48. Anderson RA. Essentiality of chromium in humans. Sci Total Environ 21. Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav 2000;71:87–94.
49. Cowburn G, Hillsdon M, Hankey CR. Obesity management by life-style 22. Thom E. Hydroxycitrate (HCA) in the treatment of obesity. Int J Obes strategies. Br Med Bull 1997;53:389 – 408.
Relat Metab Disord 1996;20(suppl):75 (abstr).
50. Blumenthal M, Goldberg A, Brinckmann J. Herbal medicine. Expanded 23. Rothacker DQ, Waitman BE. Effectiveness of a Garcinia cambogia and commission E monographs. Austin, TX: American Botanical Council, natural caffeine combination in weight loss—a double-blind, placebo- controlled pilot study. Int J Obes Relat Metab Disord 1997;21(suppl):53 51. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra 24. Antonio J, Colker CM, Torina GC, Shi Q, Brink W, Kalman D. Effects alkaloids. N Engl J Med 2000;343:1833– 8.
of a standardized guggulsterone phosphate supplement on body compo- 52. Fontanarosa PB, Rennie D, DeAngelis CD. The need for regulation of sition in overweight adults: a pilot study. Curr Ther Res 1999;60:220 –7.
dietary supplements—lessons from ephedra. JAMA 2003;289:1568 – 25. Thom E. A randomized, double-blind, placebo-controlled trial of a new weight-reducing agent of natural origin. J Int Med Res 2000;28:229 –33.
53. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur 26. Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on J Clin Nutr 1995;49(suppl):S190 –7.
obese patients: a clinical study. Int J Obes 1983;8:289 –93.
54. Nissen S, Sharp R, Ray M, et al. Effect of leucine metabolite ␤-hydroxy- 27. Nissen S, Panton L, Wilhelm R, Fuller JC Jr. Effect of ␤-hydroxy-␤- ␤-methylbutyrate on muscle metabolism during resistance-exercise methylbutyrate (HMB) supplementation on strength and body compo- training. J Appl Physiol 1996;81:2095–104.
sition of trained and untrained males undergoing intense resistance train- 55. Stanko RT, Reynolds HR, Hoyson R, Janosky JE, Wolf R. Pyruvate supplementation of a low-cholesterol, low-fat diet: effects on plasma 28. Vukovich MD, Stubbs NB, Bohlken RM, Desch MF, Fuller JC Jr, Rath- lipid concentrations and body composition in hyperlipidemic patients.
macher JA. The effect of dietary ␤-hydroxy-␤-methylbutyrate (HMB) on strength gains and body composition changes in older adults. FASEB 56. Stanko RT, Arch JE. Inhibition of regain of body weight and fat with addition of 3-carbon compounds to the diet with hyperenergetic refeed- 29. Rodríguez-Mora´n M, Guerrero-Romero F, Laczano-Burciaga. Lipid- ing after weight reduction. Int J Obes Relat Metab Disord 1996;20:925– and glucose-lowering efficacy of plantago psyllium in type II diabetes.
J Diabetes Complications 1998;12:273– 8.
57. Allison DB, Fontaine KR, Heshka S, Mentore JL, Heymsfield SB. Al- 30. Kalman D, Colker CM, Wilets I, Roufs JB, Antonio J. The effects of ternative treatments for weight loss: a critical review. Crit Rev Food Sci pyruvate supplementation on body composition in overweight individ- 58. Arterburn D, Hitchcock Noe¨l P. Obesity. BMJ 2001;322:1406 –9.
31. Kalman D, Colker CM, Stark R, Minsch A, Wilets I, Antonio J. Effects 59. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior of pyruvate supplementation on body composition and mood. Curr Ther therapy and sibutramine for the treatment of adolescent obesity. JAMA 32. Andersen T, Fogh J. Weight loss and delayed gastric emptying following 60. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, a South American herbal preparation in overweight patients. J Hum Nutr non-prescription weight loss supplements. Med J Aust 1999;171:604 – 8.
61. Hosobuchi, C, Rutanassee L, Bassin S-L, Wong N-D. Efficacy of acacia, 33. Kucio C, Jonderko K, Piskorska D. Does yohimbine act as a slimming pectin and guar gum-based fiber supplementation in the control of hy- drug? Isr J Med Sci 1991;27:550 – 6.
percholesterolaemia. Nutr Res 1999;19:643–9.
34. Sax L. Yohimbine does not affect fat distribution in men. Int J Obes 62. Najemnik C, Kritz H, Irsigler K, et al. Guar and its effects on metabolic control in type II diabetic patients. Diabetes Care 1984;7:215–20.
35. Berlin I, Stalla-Bourdillon A, Thuillier Y, Turpin G, Puech J. Lack of 63. Wirth A, Middlehoff G, Braeunig C, Schlierf G. Treatment of familial efficacity of yohimbine in the treatment of obesity. J Pharmacol (Paris) hypercholesterolaemia with a combinations of bezafibrate and guar.
36. Ernst E, Pittler MH. Chitosan as a treatment for body weight reduction? 64. Ha¨nsel R, Keller K, Rimpler H, Schneider G, eds. Hagers Handbuch der pharmazeutischen Praxis. Berlin: Springer, 1992.
37. Pittler MH, Stevinson C, Ernst E. Chromium picolinate for body weight 65. Stearns DM, Wise JP, Patierno SR, Wetterhahn KE. Chromium(III) reduction. Meta-analysis of randomized trials. Int J Obes Relat Metab picolinate produces chromosome damage in Chinese hamster ovary 38. Greenway FL. The safety and efficacy of pharmaceutical and herbal 66. Anderson RA, Bryden NA, Polansky NN. Lack of toxicity of chromium caffeine and ephedrine use as a weight loss agent. Obes Rev 2001;2: chloride and chromium picolinate in rats. J Am Coll Nutr 1997;16: 39. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra 67. Kato I, Vogelman JH, Karkoszka J, et al. Effect of supplementation with and ephedrine for weight loss and athletic performance. JAMA 2003; chromium picolinate on antibody titers to 5-hydroxymethyl uracil. Eur J 40. Pittler MH, Ernst E. Guar gum for body weight reduction. Meta-analysis 68. Hepburn DDD, Xiao J, Bindon S, Vincent JB, O’Donnell J. Nutritional of randomized trials. Am J Med 2001;110:724 –30.
supplement chromium picolinate causes sterility and lethal mutations in 41. Kanauchi O, Deuchi K, Imasato Y, Shizukuishi M, Kobayashi E. Mech- Drosophila melanogaster. Proc Natl Acad Sci U S A 2003;100:3766 – anism for the inhibition of fat digestion by chitosan and for the syner- gistic effect of ascorbate. Biosci Biotech Biochem 1995;59:786 –90.
69. Martin WR, Fuller R. Suspected chromium picolinate-induced rhabdo- 42. Nauss JL, Thompson JL, Nagyuvary J. The binding of micellar lipids to myolysis. Pharmacotherapy 1998;18:860 –2.
70. Scroggie DA, Harris M, Sakai L. Rhabdomyolysis associated with nu- 43. Nagyvary JJ, Falk JD, Hill ML, Schmidt ML, Wilkins AK, Bradbury EL.
tritional supplement use. J Clin Rheumatol 2000;6:328 –32.
The hypolipidemic activity of chitosan and other polysaccharides in rats.
71. Cerulli J, Grabe DW, Gauthier I, Malone M, McGoldrick MD. Chro- mium picolinate toxicity. Ann Pharmacother 1998;32:428 –31.
44. Vahouny GV, Satchithanandam S, Cassidy MM, Lightfood FB, Fzirda 72. Young PC, Turiansky GW, Bonner MW, Benson PM. Acute general- I. Comparative effects of chitosan and cholestyramine on lymphatic izedexanthematous pustulosis induced by chromium picolinate. J Am absorption of lipids in the rat. Am J Clin Nutr 1983;38:278 – 84.
45. Anderson RA. Effects of chromium on body composition and weight 73. Dickersin K. The existence of publication bias and risk factors for its 74. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in 78. Pittler MH, Abbot NC, Harkness EF, Ernst E. Location bias in controlled clinical research. Lancet 1991;337:867–72.
clinical trials of complementary/alternative therapies. J Clin Epidemiol 75. Egger M, Davey Smith G. Bias in location and selection of studies. BMJ 79. Egger M, Zellweger-Za¨hner T, Schneider M, Junker C, Lengeler C, 76. Ernst E, Pittler MH. Alternative therapy bias. Nature 1997;385:480 Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326 –9.
77. Schmidt K, Pittler MH, Ernst E. Bias in alternative medicine is still rife 80. Nieminen P, Isohanni M. Bias against European journals in medical but is diminishing. BMJ 2001;323:1071 (letter).
publication databases. Lancet 1999;353:1592 (letter).


Microsoft word - 2006_02 - 01 - magna cinderella review colour2.doc

CINDERELLA Saturday Night Live, it was a full house. ………… At curtain up the audience was transported into an exciting panto-land: sumptuous scenery, magnificent costumes, with quality make-up and hairstyles. ‘Spot on’ stage lighting and a crystal clear sound system further enhanced the atmosphere. The word-perfect cast (well almost!) together with the crew worked brillian

Nanotherapeutics files investigational new drug application for nanodox(tm) hydrogel to treat lower extremity diabetic ulcers

Nanotherapeutics Files Investigational New Drug Application for NanoDOX(TM) Hydrogel to Treat Lower Extremity Diabetic UlcersSeptember 04, 2008 08:50 AM Eastern Daylight Time Nanotherapeutics Files Investigational New Drug Application for NanoDOX™ Hydrogel to Treat Lower Extremity Diabetic Ulcers ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, a privately held specialty biopharmaceutica

Copyright © 2010-2014 Internet pdf articles